PB019 (guselkumab biosimilar) / Polpharma, MS Pharma - LARVOL DELTA

Polpharma Biologics S.A…announced that it has signed licensing agreements with MS Pharma…for the commercialization of its biosimilar candidates vedolizumab (PB016), ocrelizumab (PB018) and guselkumab (PB019) in the MENA region. (Businesswire) - "Under the agreements, MS Pharma will be responsible for the registration, marketing, and distribution of these three biosimilars across MENA, while Polpharma Biologics will maintain responsibility for development, manufacturing, and supply. Furthermore, both Parties have agreed to transfer fill and finish activities to the MENA region."

Commercial • Psoriasis • Psoriatic Arthritis • Ulcerative Colitis